← Leaderboards
Shlomo Melmed
Cedars-Sinai Medical Center
$23,916,451
Attributed
$23,916,451
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $10M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,962,371 · 16
FDA$1,954,080 · 1
By mechanism
R01$9,921,547 · 5
G20$9,552,872 · 1
T32$3,399,458 · 1
R21$445,279 · 1
R56$342,350 · 1
S07$200,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pituitary Neoplasms”
- Sherry McKee · Yale University$9,875,000
- Ursula B Kaiser · Brigham And Women'S Hospital$9,848,008
- Mone Zaidi · Icahn School Of Medicine At Mount Sinai$7,029,897
- Stuart C. Sealfon · Mount Sinai School Of Medicine Of Cuny$7,027,257
- Sally A. Camper · University Of Michigan At Ann Arbor$6,564,511
- Juanita L Merchant · University Of Michigan At Ann Arbor$5,741,297
Research focus
Pituitary NeoplasmsDiabetes MellitusGene ExpressionCell ProliferationTissuesPituitary GlandEndocrinologyCellsTraining ProgramsGrowthMetabolicIn VitroChromosomal InstabilityNeoplasmsMalignant NeoplasmsAdenomaSomatotropinApoptosisDna DamageIn VivoMediatingPathway InteractionsHyperplasiaPregnancy
Grant awards (70)
Mechanisms for GH action on epithelial cells$367,400
R01 · FY2025 · DK · contact PI
Ph 2 Multicenter study of seliciclib for Cushing Disease IND 120,848 (10/10/2017)$493,827
R01 · FY2024 · FD · contact PI
Mechanisms for GH action on epithelial cells$352,704
R01 · FY2024 · DK · contact PI
Ph 2 Multicenter study of seliciclib for Cushing Disease IND 120,848 (10/10/2017)$467,775
R01 · FY2023 · FD · contact PI
Mechanisms for GH action on epithelial cells$367,400
R01 · FY2023 · DK · contact PI
Training Program in Endocrinology, Diabetes, and Metabolism$234,564
T32 · FY2022 · DK · contact PI
Mechanisms for GH action on epithelial cells$382,500
R01 · FY2021 · DK · contact PI
Regulation of age-associated DNA damage$342,350
R56 · FY2021 · AG · contact PI
Training Program in Endocrinology, Diabetes, and Metabolism$212,062
T32 · FY2021 · DK · contact PI
Mechanisms for GH action on epithelial cells$382,500
R01 · FY2020 · DK · contact PI
Training Program in Endocrinology, Diabetes, and Metabolism$161,583
T32 · FY2020 · DK · contact PI
Ph 2 Multicenter study of seliciclib for Cushing Disease IND 120,848 (10/10/2017)$492,509
R01 · FY2019 · FD · contact PI
Mechanisms for GH action on epithelial cells$382,500
R01 · FY2019 · DK · contact PI
Training Program in Endocrinology, Diabetes, and Metabolism$186,914
T32 · FY2019 · DK · contact PI
Ph 2 Multicenter study of seliciclib for Cushing Disease IND 120,848 (10/10/2017)$499,969
R01 · FY2018 · FD · contact PI
Mechanisms for GH action on epithelial cells$383,625
R01 · FY2018 · DK · contact PI
Training Program in Endocrinology, Diabetes, and Metabolism$170,725
T32 · FY2018 · DK · contact PI
Training Program in Endocrinology, Diabetes, and Metabolism$211,756
T32 · FY2016 · DK · contact PI
Treatment of pituitary Cushing disease with a selective CDK inhibitor, R-roscovit$210,897
R21 · FY2015 · DK · contact PI
Training Program in Endocrinology, Diabetes, and Metabolism$195,394
T32 · FY2015 · DK · contact PI
Treatment of pituitary Cushing disease with a selective CDK inhibitor, R-roscovit$234,382
R21 · FY2014 · DK · contact PI
Training Program in Endocrinology, Diabetes, and Metabolism$71,802
T32 · FY2014 · DK · contact PI
Training Program in Endocrinology, Diabetes, and Metabolism$194,311
T32 · FY2013 · DK · contact PI
Mechanisms of Pituitary Tumorigenesis$277,093
R01 · FY2012 · CA · contact PI
Training Program in Endocrinology, Diabetes, and Metabolism$199,724
T32 · FY2012 · DK · contact PI
Mechanisms of Pituitary Tumorigenesis$277,093
R01 · FY2011 · CA · contact PI
Cedars-Sinai Biobank and Translational Research Core Facility (CS-BRCF)$9,552,872
G20 · FY2010 · RR · contact PI
Mechanisms of Pituitary Tumorigenesis$285,664
R01 · FY2010 · CA · contact PI
Training Program in Endocrinology and Diabetes$182,833
T32 · FY2010 · DK · contact PI
Training Program in Endocrinology and Diabetes$15,865
T32 · FY2010 · DK · contact PI
Mechanisms of Pituitary Tumorigenesis$285,664
R01 · FY2009 · CA · contact PI
Training Program in Endocrinology and Diabetes$176,690
T32 · FY2009 · DK · contact PI
Training Program in Endocrinology and Diabetes$15,755
T32 · FY2009 · DK · contact PI
MECHANISMS FOR PITUITARY TUMORIGENESIS$266,250
R01 · FY2008 · CA · contact PI
Training Program in Endocrinology and Diabetes$159,174
T32 · FY2008 · DK · contact PI
Training Program in Endocrinology and Diabetes$15,645
T32 · FY2008 · DK · contact PI
Metabolic consequences of securin disruption$306,828
R01 · FY2007 · DK · contact PI
MECHANISMS FOR PITUITARY TUMORIGENESIS$266,250
R01 · FY2007 · CA · contact PI
Training Program in Endocrinology and Diabetes$117,669
T32 · FY2007 · DK · contact PI
MECHANISMS FOR PITUITARY TUMORIGENESIS$863
M01 · FY2007 · RR · contact PI
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION$756
M01 · FY2007 · RR · contact PI
Metabolic consequences of securin disruption$315,991
R01 · FY2006 · DK · contact PI
MECHANISMS FOR PITUITARY TUMORIGENESIS$274,201
R01 · FY2006 · CA · contact PI
Training Program in Endocrinology and Diabetes$170,816
T32 · FY2006 · DK · contact PI
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION$2,244
M01 · FY2006 · RR · contact PI
MECHANISMS FOR PITUITARY TUMORIGENESIS$2,244
M01 · FY2006 · RR · contact PI
Metabolic consequences of securin disruption$323,595
R01 · FY2005 · DK
MECHANISMS FOR PITUITARY TUMORIGENESIS$280,800
R01 · FY2005 · CA
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION$1,797
M01 · FY2005 · RR
MECHANISMS FOR PITUITARY TUMORIGENESIS$1,797
M01 · FY2005 · RR
Gordon Research Conference on Prolactin$1
R13 · FY2005 · DK
Metabolic consequences of securin disruption$323,595
R01 · FY2004 · DK
MECHANISMS FOR PITUITARY TUMORIGENESIS$280,800
R01 · FY2004 · CA
Pituitary Tumor Surveillance: Pathogenetic Correlation$14,121
M01 · FY2004 · RR
Mechanisms for Pituitary Tumorigenesis$14,121
M01 · FY2004 · RR
Gordon Research Conference on Prolactin$7,000
R13 · FY2004 · DK
Metabolic consequences of securin disruption$323,595
R01 · FY2003 · DK
MECHANISMS FOR PITUITARY TUMORIGENESIS$255,083
R01 · FY2003 · CA
TRAINING PROGRAM IN ENDOCRINOLOGY AND DIABETES$185,011
T32 · FY2003 · DK
Quality Improvement Coalition for Human Subject Research$100,000
S07 · FY2003 · RR
Gordon Research Conference on Prolactin$1
R13 · FY2003 · DK
MECHANISMS FOR PITUITARY TUMORIGENESIS$249,568
R01 · FY2002 · CA
TRAINING PROGRAM IN ENDOCRINOLOGY AND DIABETES$183,923
T32 · FY2002 · DK
Information Technology for Human Subjects Protection$100,000
S07 · FY2002 · RR
Gordon Research Conference on Prolactin$10,000
R13 · FY2002 · DK
MECHANISMS FOR PITUITARY TUMORIGENESIS$244,214
R01 · FY2001 · CA
TRAINING PROGRAM IN ENDOCRINOLOGY AND DIABETES$159,912
T32 · FY2001 · DK
PITUITARY LIF EXPRESSION AND ACTION$273,537
R01 · FY2000 · DK
MECHANISMS FOR PITUITARY TUMORIGENESIS$239,017
R01 · FY2000 · CA
TRAINING PROGRAM IN ENDOCRINOLOGY AND DIABETES$177,330
T32 · FY2000 · DK